TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10632646

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg once daily, plus clarithromycin 250 mg and metronidazole 400 mg twice daily
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg twice daily, plus clarithromycin 250 mg and metronidazole 400 mg twice daily
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg once daily
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg twice daily
Number of subjects: 204
Study: 9212175

Group type: EXPERIMENTAL
Intervention: Low fat diet
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control (no low fat diet)
Number of subjects: 254
Study: 8020032

Group type: EXPERIMENTAL
Intervention: Indobufen (400 mg/die)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (oral, INR 2.0-3.5)
Number of subjects: 0
Study: 3313677

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 258
Study: 29240518

Group type: EXPERIMENTAL
Intervention: 90 hours of hand-arm bimanual intensive training (HABIT) over 3 weeks (Group 90, n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 45 hours of hand-arm bimanual intensive training (HABIT) over 1.5 weeks (Group 2 × 45, n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 45 hours of hand-arm bimanual intensive training (HABIT) (additional training for Group 2 × 45)
Number of subjects: 18
Study: 27384732

Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CSD)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-closed suction drainage (non-CSD)
Number of subjects: 80
Study: 25546465

Group type: COMPARATOR
Intervention: ASA 81 mg once-daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: ASA 325 mg once-daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ASA 81 mg four times daily
Number of subjects: 110
Study: 23324310

Group type: EXPERIMENTAL
Intervention: MDA measured in septic rats after intraperitoneal injection of MDR Pseudomonas aeruginosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDA measured in serum of patients with sepsis by MDR Gram-negative bacteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDA measured in serum of patients with ARDS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial measurements of MDA in serum of patients
Number of subjects: 0
Study: 21598186

Group type: EXPERIMENTAL
Intervention: Imagining themselves flossing while engaging the motor system (touching a piece of floss)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engaging the motor system during the video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watching the video without engaging the motor system
Number of subjects: 0
Study: 18576334

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly plus weekly methotrexate (MTX; > or =15 mg)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly plus weekly methotrexate (MTX; > or =15 mg) plus placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 201

Group type: COMPARATOR
Intervention: Etanercept 50 mg once weekly
Number of subjects: 201
Study: 16490020

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra), flexible-dose (25 mg, 50 mg, or 100 mg) for 10 weeks
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Baseline SEAR scores in subjects with ED
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (men without ED, did not take sildenafil)
Number of subjects: 93
Study: 14618035

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (amiodarone, propafenone, flecainide, sotalol)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy
Number of subjects: 68
Study: 11111392

Group type: EXPERIMENTAL
Intervention: ranitidine plus antibiotics
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: bismuth plus antibiotics
Number of subjects: 122

Group type: COMPARATOR
Intervention: ranitidine alone
Number of subjects: 122
Study: 9179631

Group type: EXPERIMENTAL
Intervention: Citalopram (adjuvant selective serotonin reuptake inhibitor)
Number of subjects: 0
Study: 8473405

Group type: EXPERIMENTAL
Intervention: Synthetic human GIP (1 pmol/kg.min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Synthetic human GLP-1 (0.3 pmol/kg.min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of GIP and GLP-1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lower dose of GLP-1 (0.15 pmol/kg.min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4064911

Group type: EXPERIMENTAL
Intervention: Tolerance training on Pursuit Rotor task with reinforcement (group E)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tolerance training on Pursuit Rotor task with reinforcement (group R)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pursuit Rotor task under alcohol without reinforcement (group P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pursuit Rotor task with reinforcement before alcohol (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reinforcement for Tracometer performance (group E)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reinforcement for Tracometer performance (group R)
Number of subjects: 20
Study: 29966816

Group type: EXPERIMENTAL
Intervention: Community mobilization intervention (Connect to Protect, C2P®)
Number of subjects: 1225

Group type: COMPARATOR
Intervention: Standard voluntary counseling and testing (VCT) control
Number of subjects: 1225
Study: 25946576

Group type: EXPERIMENTAL
Intervention: Carbetocin (single IV dose)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Oxytocin (IV infusion)
Number of subjects: 180
Study: 25437032

Group type: EXPERIMENTAL
Intervention: WLS Forte (FitForMe, Rotterdam, the Netherlands) - contains vitamin B12 14000% RDA, iron 500% RDA, folic acid 300% RDA
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard multivitamin supplement (sMVS) - contains approximately 100% of the recommended daily allowance (RDA) for iron, vitamin B12, and folic acid
Number of subjects: 148
Study: 23152133

Group type: EXPERIMENTAL
Intervention: OUTBACK(®) LTD Re‐Entry Catheter
Number of subjects: 52

Group type: COMPARATOR
Intervention: Manual reentry technique
Number of subjects: 52
Study: 19913611

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (0.1 mmol/kg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 9
Study: 18006892

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 435

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 435
Study: 16030050

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg bid for 1 year
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12850992

Group type: EXPERIMENTAL
Intervention: Subject-performed task (SPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal task (VT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Item-specific orienting task for VTs
Number of subjects: 0
Study: 10543488

Group type: EXPERIMENTAL
Intervention: 300 U/kg of heparin
Number of subjects: 24

Group type: COMPARATOR
Intervention: 150 U/kg of heparin
Number of subjects: 24
Study: 8983892

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Ofloxacin 400 mg twice daily
Number of subjects: 82
Study: 2029814

Group type: EXPERIMENTAL
Intervention: Tympanic thermometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral and rectal thermometers
Number of subjects: 0
Study: 35824

Group type: COMPARATOR
Intervention: salazosulphapyridine (SASP) 1 g X 3
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: methyl-salazosulphapyridine (methyl-SASP) 125 mg x 3
Number of subjects: 33
Study: 31818831

Group type: EXPERIMENTAL
Intervention: SMS intervention targeting adherence to cardiovascular medications
Number of subjects: 0
Study: 28866264

Group type: EXPERIMENTAL
Intervention: 0.9% NaCl solution 100ml/h for 3 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intravenous fluid
Number of subjects: 120
Study: 25707929

Group type: EXPERIMENTAL
Intervention: Comfilicon A
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lotrafilcon B
Number of subjects: 21
Study: 23958184

Group type: EXPERIMENTAL
Intervention: SurvivorCare intervention (nurse-led supportive care program including educational materials, tailored care plan, face-to-face consultation, and three telephone calls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual post-treatment care (control group)
Number of subjects: 0
Study: 21377071

Group type: EXPERIMENTAL
Intervention: IV lornoxicam 16 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study: 19877047

Group type: EXPERIMENTAL
Intervention: dnaJP1 (25 mg daily for 6 months)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: dnaJP1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of dnaJP1 and hydroxychloroquine (HCQ)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 16966991

Group type: EXPERIMENTAL
Intervention: Blind subxiphoid pericardiotomy (BSP)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Percutaneous catheter drainage (PCD)
Number of subjects: 83

Group type: COMPARATOR
Intervention: BSP and PCD (combined outcome)
Number of subjects: 83
Study: 15577136

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone replacement therapy
Number of subjects: 0
Study: 11133891

Group type: EXPERIMENTAL
Intervention: Training (1.5 h/day, endurance‐type exercise)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 11542396

Group type: EXPERIMENTAL
Intervention: Bright light
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: LEET
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 45
Study: 8236004

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% ophthalmic solution, four times a day for seven days
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 93
Study: 2950709

Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29566189

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation to both mother and child (MCI)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation to only the child (CI)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo control (C)
Number of subjects: 360
Study: 26852899

Group type: EXPERIMENTAL
Intervention: Pulse-PDT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: S-pulse-PDT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional PDT
Number of subjects: 22
Study: 24733880

Group type: EXPERIMENTAL
Intervention: Empowerment and self‐defense intervention (six 2‐hour sessions)
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: Empowerment and self‐defense intervention
Number of subjects: 1978

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) group (life skills class, n = 428)
Number of subjects: 1978

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) group
Number of subjects: 1978
Study: 23434302

Group type: EXPERIMENTAL
Intervention: Integrated health management model
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study: 20201959

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cross polarized light (CPL) method
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluorescence diagnosis (FD) method
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 12
Study: 17587217

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg once daily
Number of subjects: 798

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study: 15662690

Group type: EXPERIMENTAL
Intervention: Nuchal translucency measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second trimester maternal serum test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12869456

Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control tape
Number of subjects: 87

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 87
Study: 10555898

Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (8 g daily for 28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylcholine (iontophoresis)
Number of subjects: 0
Study: 8873688

Group type: EXPERIMENTAL
Intervention: Bumetanide (0.005 to 0.10 mg/kg)
Number of subjects: 58
Study: 1994758

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with midazolam (0.5 mg) and fentanyl (25 micrograms) administered via PCA infuser
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sedation administered by the anesthesiologist with 0.5‐1.0 mg intravenous midazolam and 25‐50 micrograms intravenous fentanyl
Number of subjects: 40
Study: 6659643

Group type: EXPERIMENTAL
Intervention: Disopyramide (Di) 2.0 mg/kg intravenous
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mexiletine (Me) 3.0 mg/kg intravenous
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propafenon (Pr) 1.5 mg/kg intravenous
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Disopyramide (Di) 4 X 200 mg/day oral
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mexiletine (Me) 4 X 200 mg/day oral
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propafenon (Pr) 3 X 300 mg/day oral
Number of subjects: 7
Study: 31834000

Group type: EXPERIMENTAL
Intervention: Dolutegravir + lamivudine
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Dolutegravir + tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 1433
Study: 31014344

Group type: EXPERIMENTAL
Intervention: Clarithromycin (12-week course)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally administered steroids (used as rescue medication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial design (three-arm trial)
Number of subjects: 0
Study: 28672316

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 501

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 501
Study: 25425502

Group type: EXPERIMENTAL
Intervention: linagliptin 5mg once daily
Number of subjects: 1519

Group type: COMPARATOR
Intervention: glimepiride 1-4mg once daily
Number of subjects: 1519
Study: 24012465

Group type: EXPERIMENTAL
Intervention: Compression stockings for 48 hours (Group A)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Compression stockings for 7 days (Group B)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound imaging
Number of subjects: 109
Study: 21132441

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no HIT)
Number of subjects: 20
Study: 20156769

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (960 mg thrice weekly for 18 months)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 31
Study: 16537811

Group type: EXPERIMENTAL
Intervention: Chemotherapy in CCG 2891
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: Chemotherapy in CCG 2961
Number of subjects: 1641

Group type: COMPARATOR
Intervention: CCG 2961
Number of subjects: 1641
Study: 14728579

Group type: EXPERIMENTAL
Intervention: Trial Bank system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 9870976

Group type: EXPERIMENTAL
Intervention: Cognitive expectation cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine conditioning with expectation cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine conditioning alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketorolac conditioning with expectation cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketorolac conditioning alone
Number of subjects: 0
Study: 8876546

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS), 200 micrograms once daily
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray (BDP), 168 micrograms twice daily
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 349
Study: 1832527

Group type: EXPERIMENTAL
Intervention: Clarithromycin alone for 6 weeks, then placebo plus rifampin, isoniazid, ethambutol, and clofazimine for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo alone, then clarithromycin plus rifampin, isoniazid, ethambutol, and clofazimine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo plus rifampin, isoniazid, ethambutol, and clofazimine
Number of subjects: 15
Study: 6648357

Group type: EXPERIMENTAL
Intervention: Metoprolol, administered twice daily over a period of 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol, administered for 1 week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo medication for 1 week
Number of subjects: 0
Study: 31040253

Group type: EXPERIMENTAL
Intervention: Adjuvant zoledronic acid (4 mg) intravenously at 1, 2, 3, 6, 9, and 12 months after surgery
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 14
Study: 29889851

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 267
Study: 27488378

Group type: EXPERIMENTAL
Intervention: Tobramycin-impregnated bone cement (1 g/40 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous tobramycin (control group)
Number of subjects: 15
Study: 24126931

Group type: EXPERIMENTAL
Intervention: Lanicemine (AZD6765)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22036088

Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m² and cisplatin 100 mg/m² (6 cycles)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Grades 3-4 oral mucositis
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Grades 1-2 nausea/vomiting
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Grades 1-2 thrombocytopenia
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Good histological response
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Distal tumour site
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Chondroblastic tumour
Number of subjects: 533
Study: 18982233

Group type: EXPERIMENTAL
Intervention: Family psychoeducational intervention program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 45
Study: 17092664

Group type: EXPERIMENTAL
Intervention: Estrogen therapy for 3 months followed by 3 months of continuous estrogen and progesterone combined therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Continuous estrogen and progesterone therapy for 3 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined therapy (estrogen and progesterone)
Number of subjects: 38
Study: 16187913

Group type: EXPERIMENTAL
Intervention: TSH levels below 0.3 mU/L
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Normal TSH levels (0.3-3.0 mU/L)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TSH levels above 3 mU/L
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TSH after ATDT cessation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TRAb levels in relapse group (11.1 IU/L ± 0.17)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TRAb cutoff value of 1.5 IU/L
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TRAb cutoff level of 10 IU/L
Number of subjects: 96
Study: 12362932

Group type: EXPERIMENTAL
Intervention: Seville orange juice
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 13

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 13
Study: 9854661

Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iloprost
Number of subjects: 20
Study: 7787129

Group type: EXPERIMENTAL
Intervention: saline‐polyethylene glycol solution (SPG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 2079572

Group type: EXPERIMENTAL
Intervention: 3 megaunits of recombinant interferon alfa‐2b (INTRON A, R Schering‐Plough, Essex Corporation) subcutaneously thrice weekly for 4 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 58
Study: 341941

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31298217

Group type: EXPERIMENTAL
Intervention: Graphical and tailored text-based feedback with PROMs
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Graphical feedback only
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Graphical feedback
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Text-based feedback
Number of subjects: 1386

Group type: COMPARATOR
Intervention: WHOQOL-CAT
Number of subjects: 1386
Study: 28545195

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire assessing knowledge and screening compliance
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Urban residence
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Awareness of risk factors
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Personal fears (of screening being embarrassing)
Number of subjects: 506
Study: 25714882

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (3 g/daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23949026

Group type: EXPERIMENTAL
Intervention: Premotor Therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Motor Therapy
Number of subjects: 15
Study: 21570514

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: ACEI/ARBs
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Lipid-lowering medications (LL)
Number of subjects: 973